Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Direct Meds vs Gala Health

Direct Meds
Graded #27

Lower grade

vs+4
Gala Health
Graded #8

Higher grade

The verdict

Gala Health takes it — 86/100 to 82/100.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier.

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +5
85
90
Dose & formulationDirect Meds +5
88
83
Clinical oversightGala Health +5
80
85
Labs & monitoringGala Health +5
78
83
FulfillmentGala Health +8
80
88
Contract termsGala Health +6
80
86
Direct Meds · left barGala Health · right bar

The numbers

MetricDirect MedsGala Health
WeighScore82/10086/100
GradeB−B
Scorecard rank#27#8
Semaglutide$179/moNot disclosed
Tirzepatide$224/mo$179/mo
CoverageNot publicly listedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Direct Meds

Graded #27 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed
Gala Health

Graded #8 · B

Strengths

  • Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
  • Available in all 50 states
  • Keeps a brand-name path open (Ozempic listed at $1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 31 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard